Hence, we sought to confirm these results in this anti-PD-(L)1 monotherapy validation cohort through a case cross-over analysis in the 107 of 352 (30.4%) patients with 24 tumor types who were treated with systemic therapy prior to PD-(L)1 monotherapy (Supplementary Fig. S2; Supplementary Table S4). Here, CD274 is linked to neoplasm.